CA3064136A1 - (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof - Google Patents

(+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof Download PDF

Info

Publication number
CA3064136A1
CA3064136A1 CA3064136A CA3064136A CA3064136A1 CA 3064136 A1 CA3064136 A1 CA 3064136A1 CA 3064136 A CA3064136 A CA 3064136A CA 3064136 A CA3064136 A CA 3064136A CA 3064136 A1 CA3064136 A1 CA 3064136A1
Authority
CA
Canada
Prior art keywords
formula
disorder
compound
salt
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3064136A
Other languages
English (en)
French (fr)
Inventor
Clas Sonesson
Maija BUKSA
Inese Reine
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Integrative Research Laboratories Sweden AB
Original Assignee
Integrative Research Laboratories Sweden AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Integrative Research Laboratories Sweden AB filed Critical Integrative Research Laboratories Sweden AB
Publication of CA3064136A1 publication Critical patent/CA3064136A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/11—Compounds covalently bound to a solid support
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
CA3064136A 2017-05-19 2018-05-18 (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof Pending CA3064136A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP17171938 2017-05-19
EP17171938.8 2017-05-19
EP17195451.4 2017-10-09
EP17195451 2017-10-09
EP17207406 2017-12-14
EP17207406.4 2017-12-14
EP18151428 2018-01-12
EP18151428.2 2018-01-12
PCT/EP2018/063123 WO2018211080A1 (en) 2017-05-19 2018-05-18 (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof

Publications (1)

Publication Number Publication Date
CA3064136A1 true CA3064136A1 (en) 2018-11-22

Family

ID=62599537

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3064136A Pending CA3064136A1 (en) 2017-05-19 2018-05-18 (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof

Country Status (10)

Country Link
US (3) US11078158B2 (enExample)
EP (1) EP3625213B1 (enExample)
JP (1) JP7126522B2 (enExample)
CN (1) CN110621659B (enExample)
CA (1) CA3064136A1 (enExample)
DK (1) DK3625213T3 (enExample)
ES (1) ES2943252T3 (enExample)
FI (1) FI3625213T3 (enExample)
PL (1) PL3625213T3 (enExample)
WO (1) WO2018211080A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020239568A1 (en) * 2019-05-24 2020-12-03 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
CA3180417A1 (en) * 2020-06-10 2021-12-16 Guillaume Dutheuil Synthesis of (2s,5r)-5-(2-chlorophenyl)-1-(2'-methoxy-[1,1'-biphenyl]-4-carbonyl)pyrrolidine-2-carboxylic acid
WO2025003437A1 (en) 2023-06-28 2025-01-02 Integrative Research Laboratories Sweden Ab A pharmaceutical composition comprising a fumaric acid salt of (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0586229A1 (en) * 1992-09-01 1994-03-09 Zeneca Limited 3-Hydroxy-3-(subst-akyl)-pyrrolidines as 5-lipoxygenase inhibitors
EP1582524B1 (en) 2004-04-02 2008-08-13 Ludwig Maximilians Universität Method of preparing organomagnesium compounds
CN101808987A (zh) * 2007-06-05 2010-08-18 Nsab神经研究瑞典公司分公司 作为皮层儿茶酚胺能神经传递调节剂的二取代的苯基吡咯烷
WO2010058018A1 (en) * 2008-11-24 2010-05-27 Nsab, Filial Af Neurosearch Sweden Ab, Sverige 3-phenyl-3-methoxypyrrolidine derivatives as modulators of cortical catecholaminergic neurotransmission
CN104447490B (zh) * 2014-11-19 2017-06-06 连云港恒运医药有限公司 一种质子泵抑制剂的晶型、制备中间体及其合成方法和医药用途

Also Published As

Publication number Publication date
FI3625213T3 (fi) 2023-05-29
US12091384B2 (en) 2024-09-17
ES2943252T3 (es) 2023-06-12
US20240400505A1 (en) 2024-12-05
CN110621659A (zh) 2019-12-27
JP2020520936A (ja) 2020-07-16
PL3625213T3 (pl) 2023-07-17
US20200024231A1 (en) 2020-01-23
CN110621659B (zh) 2023-02-28
DK3625213T3 (da) 2023-04-24
JP7126522B2 (ja) 2022-08-26
EP3625213A1 (en) 2020-03-25
EP3625213B1 (en) 2023-03-08
WO2018211080A1 (en) 2018-11-22
US11078158B2 (en) 2021-08-03
US20210317081A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
US20240400505A1 (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
DE69220258T2 (de) Azabicyclische Verbindungen, diese enthaltende pharmazeutische Zubereitungen und ihre therapeutische Verwendung
AU2020286003B2 (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
WO2019236889A1 (en) Novel salts and crystals
SK281813B6 (sk) Tropánové deriváty, spôsob ich prípravy, použitie a farmaceutická kompozícia s ich obsahom
US20230312573A1 (en) Novel salts, crystals, and co-crystals
KR20150036081A (ko) 카르바메이트/우레아 유도체
US20210171460A1 (en) Crystalline form of sofpironium bromide and preparation method thereof
KR102768447B1 (ko) (-)-시벤졸린 숙신산염의 신규한 제조 공정
WO2024028458A2 (en) Muscarinic receptor agonists
HK40012481B (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
HK40012481A (en) (+)-3-(2,3-difluorophenyl)-3-methoxypyrrolidine or pharmaceutically acceptable salts thereof, a process for preparation thereof and uses thereof
KR102892833B1 (ko) [2-(3-플루오로-5-메탄-술포닐페녹시)에틸](프로필)아민의 제약상 허용되는 염 및 그의 용도
EA047399B1 (ru) Фармацевтически приемлемые соли [2-(3-фтор-5-метансульфонилфенокси)этил](пропил)амина и их применение
WO2025008504A1 (en) Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof
HK40063249A (en) Pharmaceutically acceptable salts of [2-(3-fluoro-5-methane-sulfonylphenoxy)ethyl](propyl)amine and uses thereof
KR20240135640A (ko) 뉴로키닌-1 길항제 전구약물 화합물의 결정형
KR20160060188A (ko) 솔리페나신 또는 그 염의 결정형 제조방법, 이에 사용되는 신규 중간체 및 그 제조방법

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220826

EEER Examination request

Effective date: 20220826

EEER Examination request

Effective date: 20220826

EEER Examination request

Effective date: 20220826

EEER Examination request

Effective date: 20220826

EEER Examination request

Effective date: 20220826

EEER Examination request

Effective date: 20220826

EEER Examination request

Effective date: 20220826